Global Pharmacogenomic Testing Service Market to Grow at 12% CAGR Through 2034
The global market for pharmacogenomic testing services is projected to grow at a compound annual growth rate of approximately 12% through 2034, expanding from USD 8.1 billion to USD 22.4 billion.
The worldwide market for pharmacogenomic testing services is anticipating substantial growth in the coming years, with projections indicating a compound annual growth rate of around 12% through 2034. According to a report by DelveInsight, the market size is expected to increase from an estimated USD 8.1 billion in 2025 to USD 22.4 billion by 2034.
This expansion is attributed to the increasing adoption of personalized medicine and a growing recognition of genetic factors influencing drug response. Additionally, rising demand for precision therapeutics, expanding applications in oncology, psychiatry, and cardiology, and advancements in next-generation sequencing technologies are accelerating market growth. Supportive regulatory initiatives and increased healthcare investments are also facilitating the integration of pharmacogenomic testing into clinical decision-making.
North America currently represents the largest market for pharmacogenomic testing services. Reactive pharmacogenomic testing constitutes the largest segment by service type. Key players in the market include companies such as Myriad Genetics, Quest Diagnostics, and Labcorp, offering a range of genetic testing solutions.
Diagnostic and pharmaceutical companies are channeling increased investments into this sector, fostering innovation and research. Furthermore, growing awareness among healthcare professionals and rising patient empowerment are supporting the sector's development. An aging global population and the increasing prevalence of chronic diseases are also expected to continue driving demand for pharmacogenomic testing.